171 related articles for article (PubMed ID: 26031520)
21. [Optimization of mobilization regimes of blood hemopoietic stem cells in patients with multiple myeloma].
Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gribanova EO; Alekseeva IV; Drokov MIu; Kalinin NN; Gretsov EM; Kliasova GA; Savchenko VG
Ter Arkh; 2011; 83(7):50-7. PubMed ID: 21894752
[TBL] [Abstract][Full Text] [Related]
22. Matched-pair analysis of hematopoietic progenitor cell mobilization using G-CSF vs. cyclophosphamide, etoposide, and G-CSF: enhanced CD34+ cell collections are not necessarily cost-effective.
Akard LP; Thompson JM; Dugan MJ; Wiemann M; Greenspan A; Hanks S; Swinney M; Nyhuis A; Jansen J
Biol Blood Marrow Transplant; 1999; 5(6):379-85. PubMed ID: 10595815
[TBL] [Abstract][Full Text] [Related]
23. Single-dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma.
Park Y; Kim DS; Jeon MJ; Lee BH; Yu ES; Kang KW; Lee SR; Sung HJ; Nam MH; Yoon SY; Choi CW; Kang ES; Cho D; Kim K; Kim BS; Kim DW; Kim SJ
J Clin Apher; 2019 Oct; 34(5):579-588. PubMed ID: 31283042
[TBL] [Abstract][Full Text] [Related]
24. [Clinical Analysis of Autologous Peripheral Blood Hematopoietic Stem Cells Mobilization and Collection in Lymphoma Patients].
Liu H; Xi R; Bai H; Wu T
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1845-1851. PubMed ID: 38071071
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis.
Wang L; Xiang H; Yan Y; Deng Z; Li H; Li X; Liu J
Ann Hematol; 2021 Feb; 100(2):563-573. PubMed ID: 33404694
[TBL] [Abstract][Full Text] [Related]
26. Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma.
Lisenko K; Baertsch MA; Meiser R; Pavel P; Bruckner T; Kriegsmann M; Schmitt A; Witzens-Harig M; Ho AD; Hillengass J; Wuchter P
Transfusion; 2017 Oct; 57(10):2359-2365. PubMed ID: 28653421
[TBL] [Abstract][Full Text] [Related]
27. Factors influencing G-CSF-mediated mobilization of hematopoietic progenitor cells during steady-state hematopoiesis in patients with malignant lymphoma and multiple myeloma.
Kobbe G; Söhngen D; Bauser U; Schneider P; Germing U; Thiele KP; Rieth C; Hünerlitürkoglu A; Fischer J; Frick M; Wernet P; Aul C; Heyll A
Ann Hematol; 1999 Oct; 78(10):456-62. PubMed ID: 10550556
[TBL] [Abstract][Full Text] [Related]
28. Recombinant human thrombopoietin improves the efficacy of intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor in mobilizing peripheral blood stem cells in patients with multiple myeloma: A cohort study.
Wang G; Chen W; Wu Y; Li Y; Leng Y; Liu A
Medicine (Baltimore); 2017 Dec; 96(50):e9302. PubMed ID: 29390394
[TBL] [Abstract][Full Text] [Related]
29. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G
Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592
[TBL] [Abstract][Full Text] [Related]
30. Effective mobilization with etoposide and cyclophosphamide for collection of peripheral blood stem cell in patients with multiple myeloma.
Wang X; Zhang Y; Fan T; Liu H; Wang M; Liu H; Zhang M; He P
Clin Invest Med; 2020 Sep; 43(3):E27-32. PubMed ID: 32971582
[TBL] [Abstract][Full Text] [Related]
31. Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen.
Nazha A; Cook R; Vogl DT; Mangan PA; Gardler M; Hummel K; Cunningham K; Luger SM; Porter DL; Schuster S; O'Doherty U; Siegel D; Stadtmauer EA
Bone Marrow Transplant; 2011 Jan; 46(1):59-63. PubMed ID: 20421869
[TBL] [Abstract][Full Text] [Related]
32. Filgrastim alone versus cyclophosphamide and filgrastim for mobilization in multiple myeloma patients.
Sarıcı A; Erkurt MA; Bahçecioğlu ÖF; Gök S; Kuku İ; Biçim S; Berber İ; Kaya E; Özgül M
Transfus Apher Sci; 2021 Aug; 60(4):103159. PubMed ID: 34034961
[TBL] [Abstract][Full Text] [Related]
33. Mobilization of hematopoietic stem cells with lenograstim in multiple myeloma patients: Prospective multicenter observational study (KMM122).
Jung EH; Byun JM; Shin DY; Do YR; Jo JC; Lee SM; Yoon SS
Cancer Med; 2023 Apr; 12(8):9186-9193. PubMed ID: 36951655
[TBL] [Abstract][Full Text] [Related]
34. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma.
Fruehauf S; Klaus J; Huesing J; Veldwijk MR; Buss EC; Topaly J; Seeger T; Zeller LW; Moehler T; Ho AD; Goldschmidt H
Bone Marrow Transplant; 2007 Jun; 39(12):743-50. PubMed ID: 17450182
[TBL] [Abstract][Full Text] [Related]
35. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma.
Hiwase DK; Bollard G; Hiwase S; Bailey M; Muirhead J; Schwarer AP
Cytotherapy; 2007; 9(6):539-47. PubMed ID: 17882718
[TBL] [Abstract][Full Text] [Related]
36. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
37. EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells.
Hart C; Grassinger J; Andreesen R; Hennemann B
Bone Marrow Transplant; 2009 Feb; 43(3):197-206. PubMed ID: 18806833
[TBL] [Abstract][Full Text] [Related]
38. Successful mobilization of peripheral blood HPCs with G-CSF alone in patients failing to achieve sufficient numbers of CD34+ cells and/or CFU-GM with chemotherapy and G-CSF.
Fraipont V; Sautois B; Baudoux E; Pereira M; Fassotte MF; Hermanne JP; Jérusalem G; Longrée L; Schaaf-Lafontaine N; Fillet G; Beguin Y
Transfusion; 2000 Mar; 40(3):339-47. PubMed ID: 10738037
[TBL] [Abstract][Full Text] [Related]
39. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM
J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
[TBL] [Abstract][Full Text] [Related]
40. Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma.
Shimura Y; Kuroda J; Uchiyama H; Kawata-Iida E; Tsutsumi Y; Nagoshi H; Mizutani S; Yamamoto-Sugitani M; Matsumoto Y; Kobayashi T; Horiike S; Shimazaki C; Kaneko H; Kobayashi Y; Taniwaki M
J Clin Apher; 2013 Oct; 28(5):368-73. PubMed ID: 23804501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]